Primer on Tumor Immunology and Cancer Immunotherapy™

Primer on Tumor Immunology and Cancer Immunotherapy™

A Pre-Conference Program; additional registration is required.

Thursday, Nov. 11, 2021*
8 a.m. – 5:30 p.m. EST

*Dates and times subject to change. 


The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. This year, the Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC attendees.

Program Organizers

  • Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
  • Yvonne Saenger, MD – Columbia University Irving Medical Center 


Target Audience

The target audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, pharmacists and registered nurses.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Review current approaches to immunotherapy including immune checkpoint modulation, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer and bispecific antibodies
  • Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

Continuing Education

This program will be accredited to offer CME, CNE, CPE and MOC credits.


Program Schedule*

*Program schedule subject to change. 

Session I: Generating Anti-Tumor Immunity
8 – 9:55 a.m. EST

8 a.m. EST Introduction
Yvonne Saenger, MD – Columbia University Irving Medical Center  

8:05 a.m.  Adaptive Immune Response (Overview)
Jonathan D. Powell, MD, PhD – Johns Hopkins University School of Medicine

8:35 a.m.  Innate Immune Response (Overview)
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital

9:05 a.m.  Dendritic Cells and Myeloid cues in the Tumor Microenvironment
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine

9:35 a.m. Session I Panel Discussion 
Moderator:
Yvonne Saenger, MD – Columbia University Irving Medical Center
Panelists: Session I Speakers

9:55 a.m. Break

Session II: Approaches to Immunotherapy I
10:10 a.m. – 12:00 p.m. EST

10:10 a.m. T cell Checkpoint Blockade
James P. Allison, PhD - The University of Texas MD Anderson Cancer Center

10:40 a.m. Myeloid-derived Suppressor Cells
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca

11:10 a.m. Cancer Vaccines

11:40 a.m. Session II Panel Discussion 
Moderator:
Yvonne Saenger, MD – Columbia University Irving Medical Center
Panelists:
Session II Speakers

12:00 p.m. Lunch

Session III: Approaches to Immunotherapy II

1:30 – 3:25 p.m. EST

1:30 p.m. Introduction
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital

1:35 p.m. CARs (T, NK, Macrophages)
Carl H. June, MD - University of Pennsylvania

2:05 p.m. Microbiome
Thomas J. Gajewski, MD, PhD - University of Chicago

2:35 p.m. Immunometabolism
Greg M. Delgoffe, PhD - University of Pittsburgh

3:05 p.m. Session III Panel Discussion 
Moderator:
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists:
Session III Speakers

3:25 p.m. Break

Session IV: Clinical Practice of Immunotherapy

3:40 – 5:30 p.m. EST

3:40 p.m. Immune Biomarkers to Guide Clinical Care
Yvonne Saenger, MD - Columbia University Irving Medical Center

4:10 p.m. Immune Related Adverse Events
Anna C. Pavlick, MD, MBA - Weill Cornell Medicine

4:40 p.m. The State of Immunotherapy/Progress in Immunotherapy
James L. Gulley, MD, PhD, FACP - National Cancer Institute

5:10 p.m. Session IV Panel Discussion 
Moderator:
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital
Panelists:
Session IV Speakers

5:25 p.m. Closing Remarks
Jennifer L. Guerriero, PhD – Brigham and Women's Hospital


Jointly_Accredited_Provider_Logo.jpg

SITC_Primer_2019.jpg
SITC_2019_Primer_2.jpg